ELEVElevation Oncology Inc

$0.00
$0.00
(0.00%)
Today
Updated:
Mkt Cap$21.63M
Vol4.82M
News
all
press releases
News Placeholder
Allogene's Q1 Earnings In Line With Estimates, Sales Nil
Zacks
News Placeholder
Elevation Oncology downgraded as it halts lead asset on disappointing trials
Investing.com -- Wall Street cut rating on Elevation Oncology Inc (NASDAQ:ELEV) after the company announced it will discontinue development of its lead asset, EO-3021, due to disappointing efficacy in a Phase 1 trial. Analysts now see limited near-term catalysts, with Elevation pivoting to its HER3-targeted ADC, EO-1022, which is still in preclinical development.
investing.com
<
...
1
>